Hypofractionated Radiotherapy Concomitantly With Weekly Boost for Breast Cancer Patients Treated With Conservative Breast Surgery
- Conditions
- Breast Cancer
- Registration Number
- NCT04815642
- Lead Sponsor
- Assiut University
- Brief Summary
This is a retrospective study on evaluation of the efficacy and the safety of a hypofractionated radiotherapy course with weekly concomitant boost for breast cancer patients treated with conservative breast surgery .
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- women aged from 18 and up to 55 years old.
- Histologically diagnosed with breast carcinoma (ductal and others )
- All patients with conservative breast surgery.
- Including all patients with in all stages except those stage IV.
- All patients with clear free surgical margin.
- patients received hypofractionated radiotherapy with weekly concomitant boost
Exclusion Criteria
- Evidence of distant metastatic deposites.
- patients with mastectomy
- patients with prior irradiation to thoracic region.
- pregnancy or lactation.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease free survival baseline Disease Free survival
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are modulated by hypofractionated radiotherapy with weekly boost in breast cancer patients post-conservative surgery?
How does hypofractionated RT with weekly boost compare to conventional fractionation in local recurrence rates for hormone receptor-positive breast cancer?
Which biomarkers (e.g., Ki-67, HER2 status) predict favorable outcomes in NCT04815642 hypofractionated radiotherapy for breast cancer?
What acute and late toxicities are reported in hypofractionated RT plus weekly boost regimens for breast cancer after lumpectomy?
Are there synergistic effects when combining hypofractionated radiotherapy with weekly boost and CDK4/6 inhibitors in HER2-negative breast cancer patients?